Diabetes pill trial offers new hope for kids with tough cancers
NCT ID NCT05521984
Summary
This early-stage study is testing whether adding the diabetes drug dapagliflozin to standard cancer treatment is safe for children and young adults with recurrent brain tumors or solid tumors that have come back or resisted treatment. The main goal is to check for side effects, but researchers also hope the drug might help shrink tumors by changing how cancer cells use energy. The study will enroll about 20 participants aged 6 to 21 who have no other curative options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine/St. Louis Children's Hospital
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.